Cover Image
市場調查報告書

組蛋白去乙醯酶1 (EC 3.5.1.98) :開發中產品分析

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 363131
出版日期 內容資訊 英文 110 Pages
訂單完成後即時交付
價格
Back to Top
組蛋白去乙醯酶1 (EC 3.5.1.98) :開發中產品分析 Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 110 Pages
簡介

本報告提供組蛋白去乙醯酶1 (EC 3.5.1.98)的開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等系統性資訊。

目錄

簡介

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

開發中的產品:各企業

開發中的產品:各大學/研究機關

治療藥的評估

  • 單劑/聯合治療別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • 4SC AG
  • Acetylon Pharmaceuticals, Inc.
  • Chipscreen Biosciences Ltd
  • Curis, Inc.
  • GlaxoSmithKline Plc
  • HitGen LTD
  • IRBM Science Park SpA
  • Italfarmaco S.p.A.
  • MEI Pharma, Inc.
  • Merck & Co., Inc.
  • Mirati Therapeutics Inc.
  • Oncolys BioPharma Inc.
  • Sigma-Tau S.p.A.
  • Syndax Pharmaceuticals, Inc.
  • TetraLogic Pharmaceuticals

藥物簡介

暫停的計劃

最新消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0601TDB

Summary

Global Markets Direct's, 'Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H2 2016', provides in depth analysis on Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted pipeline therapeutics.

The report provides comprehensive information on the Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)
  • The report reviews Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Overview
  • Therapeutics Development
    • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Products under Development by Stage of Development
    • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Products under Development by Therapy Area
    • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Products under Development by Indication
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Products under Development by Companies
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Products under Development by Universities/Institutes
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
    • 4SC AG
    • Acetylon Pharmaceuticals, Inc.
    • Chipscreen Biosciences Ltd
    • Curis, Inc.
    • GlaxoSmithKline Plc
    • HitGen LTD
    • IRBM Science Park SpA
    • Italfarmaco S.p.A.
    • MEI Pharma, Inc.
    • Merck & Co., Inc.
    • Mirati Therapeutics Inc.
    • Oncolys BioPharma Inc
    • Sigma-Tau S.p.A.
    • Syndax Pharmaceuticals Inc
    • TetraLogic Pharmaceuticals
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Drug Profiles
    • 4SC-202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACY-738 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACY-957 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • crocetin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CS-3158 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CUDC-907 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • entinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • givinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HG-3001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Largazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mocetinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OBP-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pracinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • remetinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Histone Deacetylase 1 for Beta Thalassemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Histone Deacetylases for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit BRD4 and HDAC1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ST-3595 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tucidinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vorinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Dormant Projects
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Featured News & Press Releases
    • Aug 01, 2016: MEI Pharmas Pracinostat Receives Breakthrough Therapy Designation from FDA for Treatment in Combination with Azacitidine of Patients with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Chemotherapy
    • Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association
    • Jun 05, 2016: Mirati Therapeutics Provides Update On Mocetinostat Program
    • Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting
    • May 18, 2016: Entinostat Data to be Highlighted at the American Society of Clinical Oncology 2016 Annual Meeting
    • May 04, 2016: Acetylon Pharmaceuticals Publishes New Mechanism for the Treatment of Sickle Cell Disease/Beta-Thalassemia with Selective HDAC1/2 Inhibition in PLoS One
    • Apr 11, 2016: Syndax Announces Entinostat Data to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting
    • Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting
    • Apr 04, 2016: Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology
    • Mar 24, 2016: Mirati Therapeutics To Present Mocetinostat Preclinical Data At 2016 American Association For Cancer Research Annual Meeting
    • Mar 21, 2016: Epigenetic compound 4SC-202 strengthens endogenous immune response to cancer
    • Mar 03, 2016: HUYA Bioscience International Expands Senior Management Team
    • Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan
    • Dec 07, 2015: MEI Pharma Announces Positive Results from Phase II Study of Pracinostat in Acute Myeloid Leukemia, Plans to Initiate Phase III Registration Study
    • Dec 07, 2015: Acetylon Presents Data on the Pharmacokinetics and HbE/HbG Hemoglobin Induction Following Once Daily Dosing of an Oral HDAC1,2 Inhibitor in Animal Models
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by 4SC AG, H2 2016
  • Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016
  • Pipeline by Chipscreen Biosciences Ltd, H2 2016
  • Pipeline by Curis, Inc., H2 2016
  • Pipeline by GlaxoSmithKline Plc, H2 2016
  • Pipeline by HitGen LTD, H2 2016
  • Pipeline by IRBM Science Park SpA, H2 2016
  • Pipeline by Italfarmaco S.p.A., H2 2016
  • Pipeline by MEI Pharma, Inc., H2 2016
  • Pipeline by Merck & Co., Inc., H2 2016
  • Pipeline by Mirati Therapeutics Inc., H2 2016
  • Pipeline by Oncolys BioPharma Inc, H2 2016
  • Pipeline by Sigma-Tau S.p.A., H2 2016
  • Pipeline by Syndax Pharmaceuticals Inc, H2 2016
  • Pipeline by TetraLogic Pharmaceuticals, H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Dormant Projects (Contd..2), H2 2016
  • Dormant Projects (Contd..3), H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top